Promotes Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy
Promotes Chief Financial Officer Matthew Pigeon to Chief Financial Officer and Senior Vice President
SANTA BARBARA, Calif., Feb. 01, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the promotion of Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy, effective immediately. In addition to continuing to lead the Company’s business development and strategy, Mr. Huiner will assume responsibility for Sientra’s manufacturing operations, clinical operations and legal affairs functions.
The Company also announced the promotion of Matthew Pigeon to Senior Vice President in addition to his role as Chief Financial Officer and Treasurer.
Jeffrey Nugent, Chairman and Chief Executive Officer of Sientra, said, “Since joining the Sientra team in 2014, Charlie has demonstrated the ability to think strategically and facilitate a high level of cooperation and execution across the Company. His increased responsibilities at this time are critical to help coordinate the important cross functional priorities we have in front of us, including the ongoing development and execution of our manufacturing and supply chain strategy. Matt’s role in financial planning and control as well as the overall strategic direction of the Company will continue to be critical to our success. We congratulate both Charlie and Matt in their new roles and look forward to their continued contributions.”
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
Investor Contacts: The Ruth Group Nick Laudico / Brandon Vazquez (646) 536-7030 / 7032 [email protected]


BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 



